NOTE: Our website has moved --> NEW WEBSITE

 

Originally founded as a junior research group at the Heidelberg University Cluster of Excellence CellNetworks in October 2007, we have grown over the past 11 years into a team of currently 15 people that focuses on

• (1) development of designer Adeno-associated viruses (AAV) as efficient, safe & specific vectors for human gene transfer & therapy,
• (2) combination of AAV with the latest CRISPR/Cas9 gene/genome engineering technologies,
• (3) basic mechanisms and therapeutic applications of RNA interference (RNAi) in the context of pathogen-host interactions,
• (4) synergistic use of these 3 key technologies for novel gene therapies against infectious diseases, especially hepatitis, AIDS & malaria
• (5) application of AAV vectors for in vitro and in vivo generation and study of induced pluripotent stem cells (iPSC)